TY - JOUR
KW - Humans
KW - Hypoglycemic Agents/adverse effects
KW - *Diabetes Mellitus, Type 2/drug therapy
KW - *Dipeptidyl-Peptidase IV Inhibitors/adverse effects
KW - *Sodium-Glucose Transporter 2 Inhibitors/adverse effects
KW - Glucagon-Like Peptide-1 Receptor/agonists
KW - Cohort Studies
KW - Sulfonylurea Compounds/adverse effects
KW - *Pulmonary Disease, Chronic Obstructive/drug therapy
AU - R. Pradhan
AU - S. Lu
AU - H. Yin
AU - O. H. Y. Yu
AU - P. Ernst
AU - S. Suissa
AU - L. Azoulay
AD - Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, QC, Canada.
Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, QC, Canada.
Division of Endocrinology, Jewish General Hospital, Montreal, QC, Canada.
Department of Medicine, McGill University, Montreal, QC, Canada.
Gerald Bronfman Department of Oncology, McGill University, Montreal, QC, Canada.
AN - 36318979
BT - Bmj
C2 - PMC9623550 at https://www.icmje.org/disclosure-of-interest/ and declare: this study was funded by the Canadian Institutes of Health Research; LA has received consulting fees from Janssen and Pfizer unrelated to this project; SS has attended scientific advisory committee meetings for AstraZeneca, Atara, Bristol-Myers-Squibb, Merck, Novartis, Panalgo, Pfizer, and Seqirus and has received speaking fees from Boehringer-Ingelheim and Novartis; no other relationships or activities that could appear to have influenced the submitted work.
DO - 10.1136/bmj-2022-071380
DP - NLM
ET - 2022/11/02
LA - eng
N1 - 1756-1833
Pradhan, Richeek
Lu, Sally
Yin, Hui
Yu, Oriana H Y
Ernst, Pierre
Suissa, Samy
Azoulay, Laurent
Orcid: 0000-0001-5162-3556
Journal Article
England
BMJ. 2022 Nov 1;379:e071380. doi: 10.1136/bmj-2022-071380.
PY - 2022
SN - 0959-8138 (Print)
0959-8138
EP - e071380
T2 - Bmj
TI - Novel antihyperglycaemic drugs and prevention of chronic obstructive pulmonary disease exacerbations among patients with type 2 diabetes: population based cohort study
VL - 379
ER -